Search Results

• • 12 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• An overview of new biomolecular pathways in pathogen-related cancers

  Authors:Maria Lina Tornesello, Luigi Buonaguro, and Franco M BuonaguroFrom:Future Oncology (Vol. 11, Issue 11) Peer-Reviewed

  June 201511,332 words Report 2070LAuthor(s): Maria Lina Tornesello aff1 , Luigi Buonaguro aff1 , Franco M Buonaguro [*] aff1 KEYWORDS biomarkers; cancer oncogenic pathogens; cell cycle; pathways Cancer arises from the progressive accumulation...

• Identification of melanoma initiating cells: does CD271 have a future?

  Author:Robert BallottiFrom:Future Oncology (Vol. 11, Issue 11) Peer-Reviewed

  June 20152,572 words Article 1990LAuthor(s): Robert Ballotti [*] KEYWORDS drug resistance; melanoma; plasticity; surface marker; tumorigenicity Melanoma facts Melanoma is one of the few cancers whose incidence has constantly been increasing...

• EGFR mutations in lung cancer: from tissue testing to liquid biopsy

  Authors:Francesca Fenizia, Antonella De Luca, Raffaella Pasquale, Alessandra Sacco, Laura Forgione, Matilde Lambiase, et al.From:Future Oncology (Vol. 11, Issue 11) Peer-Reviewed

  June 20159,703 words Report 1950LAuthor(s): Francesca Fenizia aff1 , Antonella De Luca aff2 , Raffaella Pasquale aff1 , Alessandra Sacco aff1 , Laura Forgione aff1 , Matilde Lambiase aff1 , Alessia Iannaccone aff1 , Nicoletta Chicchinelli aff2 , Renato...

• Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma

  Authors:Maria J Cejalvo and Javier de la RubiaFrom:Future Oncology (Vol. 11, Issue 11) Peer-Reviewed

  June 201511,102 words Report 1830LAuthor(s): María J Cejalvo aff1 , Javier de la Rubia [*] aff1 aff2 KEYWORDS front-line therapy; immunomodulatory drugs; lenalidomide; multiple myeloma Multiple myeloma (MM) is a malignant B-cell disorder...

• SUMO pathway components as possible cancer biomarkers

  Authors:Domenico Mattoscio and Susanna ChioccaFrom:Future Oncology (Vol. 11, Issue 11) Peer-Reviewed

  June 20159,334 words Report 2050LAuthor(s): Domenico Mattoscio aff1 , Susanna Chiocca [*] aff1 KEYWORDS biomarkers; cancer; SAE1/2; SUMO; SUMO ligases; SUMO proteases; Ubc9 Small Ubiquitin-related MOdifier (SUMO) is a post-translational...

• Corrigendum

  From:Future Oncology (Vol. 11, Issue 11) Peer-Reviewed

  June 2015175 words Brief article, Corre... 1250LFollowing publication of the Review by Qian Huang & Xuenong Ouyang titled 'The role of miRNAs in bone metastasis and their significance in the detection of bone metastasis: a review of the published data', which...

• Cellular prognostic markers in hepatocellular carcinoma

  Authors:Luigi Buonaguro, Maria Tagliamonte, Annacarmen Petrizzo, Elvira Damiano, Maria Lina Tornesello, and Franco M BuonaguroFrom:Future Oncology (Vol. 11, Issue 11) Peer-Reviewed

  June 20156,290 words Report 2000LAuthor(s): Luigi Buonaguro [*] aff1 , Maria Tagliamonte aff1 , Annacarmen Petrizzo aff1 , Elvira Damiano aff1 , Maria Lina Tornesello aff1 , Franco M Buonaguro aff1 KEYWORDS cancer-associated fibroblasts; hepatic...

• 3q26/EVI1 rearrangements in myeloid hemopathies: a cytogenetic review

  Authors:Marc De Braekeleer, Marie-Josee Le Bris, Etienne De Braekeleer, Audrey Basinko, Frederic Morel, and Nathalie Douet-GuilbertFrom:Future Oncology (Vol. 11, Issue 11) Peer-Reviewed

  June 20157,315 words Report 1580LAuthor(s): Marc De Braekeleer [*] aff1 aff2 aff3 , Marie-Josée Le Bris aff3 , Etienne De Braekeleer aff4 aff5 , Audrey Basinko aff2 aff3 , Frédéric Morel aff1 aff2 aff3 , Nathalie Douet-Guilbert aff1 aff2 aff3...

• Cancer biomarkers

  Authors:Franco M Buonaguro, Maria Lina Tornesello, and Luigi BuonaguroFrom:Future Oncology (Vol. 11, Issue 11) Peer-Reviewed

  June 20151,097 words Article 1780LAuthor(s): Franco M Buonaguro [*] aff1 , Maria Lina Tornesello aff1 , Luigi Buonaguro aff1 KEYWORDS cancer biomarkers; cancer determinants; cancer pathways; HCC; lung cancer; melanoma; SUMO pathway Cancer...

• Chemotherapy-associated anemia in patients with lung cancer: an epidemiological, retrospective and multicenter study

  Authors:Jose Munoz-Langa, Javier De Castro, Pere Gasco, Alfredo Sanchez, Emilio Esteban, Jose Manuel Gasent, et al.From:Future Oncology (Vol. 11, Issue 11) Peer-Reviewed

  June 20155,245 words Report 1560LAuthor(s): Jose Muñoz-Langa [*] aff1 , Javier De Castro aff2 , Pere Gascó aff3 , Alfredo Sanchez aff4 , Emilio Esteban aff5 , Jose Manuel Gasent aff6 , Isidoro Barneto aff7 , Joaquin Montalar aff8 , Angel Artal aff9 ,...

• Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review

  Authors:Zebo Huang, Yinxia Wu, Xin Zhou, Jiaqi Qian, Wei Zhu, Yongqian Shu, et al.From:Future Oncology (Vol. 11, Issue 11) Peer-Reviewed

  June 20158,667 words Report 1640LAuthor(s): Zebo Huang aff1 , Yinxia Wu aff2 , Xin Zhou aff1 , Jiaqi Qian aff1 , Wei Zhu [*] aff1 , Yongqian Shu aff1 , Ping Liu aff1 KEYWORDS clinical trials; mTOR inhibitor; solid tumor Increasingly, numerous...

• Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.

  Authors:Armin Rashidi and Amanda F CashenFrom:Future Oncology (Vol. 11, Issue 11) Peer-Reviewed

  June 20154,258 words Report 1450LABSTRACT The prognosis of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) remains poor and current treatments are typically of limited benefit. Histone deacetylase (HDAC) inhibitors have proven...